Matthew P Cheng1, Pierre René2, Alexandre P Cheng3, Todd C Lee4. 1. Division of Infectious Diseases and Department of Medical Microbiology, McGill University Health Centre, Montréal, Quebec, Canada. Electronic address: matthew.cheng@mail.mcgill.ca. 2. Division of Infectious Diseases and Department of Medical Microbiology, McGill University Health Centre, Montréal, Quebec, Canada. 3. École Polytechnique de Montréal, Montréal, Quebec, Canada. 4. Division of Infectious Diseases and Department of Medical Microbiology, McGill University Health Centre, Montréal, Quebec, Canada; Division of General Internal Medicine and Department of Medicine, McGill University Health Centre, Montréal, Quebec, Canada.
Abstract
BACKGROUND: Widespread penicillin usage rapidly resulted in the emergence of penicillin resistance in Staphylococcus aureus. However, new data suggest that penicillin susceptibility may be in a period of renaissance. The objective of our study was to quantify penicillin resistance in methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. METHODS: We retrospectively reviewed all adult MSSA bacteremia from April 2010 to April 2015 at the McGill University Health Centre (Montreal, QC, Canada). Susceptibility to penicillin, erythromycin, clindamycin, and trimethoprim-sulfamethoxazole (TMP-SMX) was determined in accordance with the Clinical & Laboratory Standards Institute guidelines. RESULTS: There were 324 unique episodes of MSSA bacteremia. Ninety (28%) isolates were susceptible to penicillin, 229 (71%) to erythromycin, 239 (74%) to clindamycin, and 317 (98%) to TMP-SMX. Isolates that were penicillin resistant were more likely to also be resistant to other antibiotics, but a statistically significant association was apparent only for erythromycin resistance (76/234, 32.2% vs 19/90, 21.1%, P = .04). The median age of patients was 67.5 years (interquartile range 52-78) and overall in-hospital 30-day mortality was 16.3% (53 deaths). After adjustment for patient age, there was no association between penicillin resistance and either intensive care unit admission or death. CONCLUSION: More than one-quarter of patients with MSSA bacteremia potentially could be treated with parenteral penicillin, which may offer pharmacokinetic advantages over other beta-lactam drugs and potentially improved outcomes.
BACKGROUND: Widespread penicillin usage rapidly resulted in the emergence of penicillin resistance in Staphylococcus aureus. However, new data suggest that penicillin susceptibility may be in a period of renaissance. The objective of our study was to quantify penicillin resistance in methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. METHODS: We retrospectively reviewed all adult MSSA bacteremia from April 2010 to April 2015 at the McGill University Health Centre (Montreal, QC, Canada). Susceptibility to penicillin, erythromycin, clindamycin, and trimethoprim-sulfamethoxazole (TMP-SMX) was determined in accordance with the Clinical & Laboratory Standards Institute guidelines. RESULTS: There were 324 unique episodes of MSSA bacteremia. Ninety (28%) isolates were susceptible to penicillin, 229 (71%) to erythromycin, 239 (74%) to clindamycin, and 317 (98%) to TMP-SMX. Isolates that were penicillin resistant were more likely to also be resistant to other antibiotics, but a statistically significant association was apparent only for erythromycin resistance (76/234, 32.2% vs 19/90, 21.1%, P = .04). The median age of patients was 67.5 years (interquartile range 52-78) and overall in-hospital 30-day mortality was 16.3% (53 deaths). After adjustment for patient age, there was no association between penicillin resistance and either intensive care unit admission or death. CONCLUSION: More than one-quarter of patients with MSSA bacteremia potentially could be treated with parenteral penicillin, which may offer pharmacokinetic advantages over other beta-lactam drugs and potentially improved outcomes.
Authors: Sanjat Kanjilal; Mohamad R Abdul Sater; Maile Thayer; Georgia K Lagoudas; Soohong Kim; Paul C Blainey; Yonatan H Grad Journal: J Clin Microbiol Date: 2017-12-26 Impact factor: 5.948
Authors: Matthew P Cheng; Alexander Lawandi; Guillaume Butler-Laporte; Katryn Paquette; Todd C Lee Journal: Trials Date: 2018-05-29 Impact factor: 2.279
Authors: Daniel J Diekema; Michael A Pfaller; Dee Shortridge; Marcus Zervos; Ronald N Jones Journal: Open Forum Infect Dis Date: 2019-03-15 Impact factor: 3.835
Authors: Edward Goldstein; Scott W Olesen; Zeynal Karaca; Claudia A Steiner; Cecile Viboud; Marc Lipsitch Journal: BMC Public Health Date: 2019-08-19 Impact factor: 3.295
Authors: Geoffrey W Coombs; Nicholas W T Yee; Denise Daley; Catherine M Bennett; James O Robinson; Marc Stegger; Princy Shoby; Shakeel Mowlaboccus Journal: Microorganisms Date: 2022-08-15
Authors: Robert Skov; David R Lonsway; Jesper Larsen; Anders Rhod Larsen; Jurgita Samulioniené; Brandi M Limbago Journal: J Antimicrob Chemother Date: 2021-05-12 Impact factor: 5.758